Alterity Therapeutics (PRNAD) Enterprise Value (2009 - 2025)

Alterity Therapeutics (PRNAD) has reported Enterprise Value for 16 consecutive years, with -$32.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Enterprise Value fell 988.88% year-over-year to -$32.3 million; the TTM figure through Dec 2025 stood at -$32.3 million (down 988.88% YoY), while the FY2025 annual figure was -$21.3 million, down 154.46% from the prior year.
• Enterprise Value came in at -$32.3 million for Q4 2025 at Alterity Therapeutics, down from -$21.3 million in the prior quarter.
• The five-year high for Enterprise Value was -$184314.5 in Q2 2023, with the low at -$32.3 million in Q4 2025.
• Average Enterprise Value over 5 years is -$16.3 million, with a median of -$20.9 million recorded in 2021.
• Across the five-year window, Enterprise Value soared 99.26% in 2023 and plunged 4433.63% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$20.5 million in 2021, then declined by 11.65% to -$22.9 million in 2022, then surged by 64.93% to -$8.0 million in 2023, then jumped by 63.01% to -$3.0 million in 2024, then sank by 988.88% to -$32.3 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$32.3 million, -$21.3 million, and -$3.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.